Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aura Biosciences, Inc.NASDAQ: AURA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $27.96M rose 19.8% year over year, ahead of the +19.3% change in trailing-twelve-month research & development. Sequentially, it rose 27.7% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +19.8% holds above the trailing-twelve-month pace of +19.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 90.3M USD
- Year-over-year change
- +23.2%
- 4-year CAGR
- +37.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.3M | +23.2% |
| FY2024 | 2024-12-31 | 73.3M | +14.6% |
| FY2023 | 2023-12-31 | 63.94M | +51.4% |
| FY2022 | 2022-12-31 | 42.24M | +67.9% |
| FY2021 | 2021-12-31 | 25.16M | — |
Research & Development vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.3% is the 6th highest of 11, against a peer median of +27.4%.
- Over three fiscal years its annual growth of +28.8% compares with a peer median of +53.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $236.54M USD | +35.6% | +95.7% | — | |
| LTM Mar 2026 | $234.61M USD | +45.4% | +64.5% | 3080.9% | |
| LTM Mar 2026 | $230.13M USD | +16.7% | +43.3% | 362.4% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M USD | +115.1% | +40.7% | — |
| LTM Mar 2026 | $94.92M USD | +19.3% | +28.8% | — | |
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| FY2025 | $67.45M USD | +64.7% | +67.7% | 1038.2% | |
| LTM Mar 2026 | CHF 56.48M CHF | +0.9% | +34.9% | 11206.4% | |
| LTM Mar 2026 | $41.48M USD | +19.1% | -10.9% | 928.9% | |
| LTM Mar 2026 | $21.25M USD | -43.8% | +8527.1% | 6378.2% | |
| Peer median (excluding AURA) | — | +27.4% | +53.2% | 1038.2% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.3M | 0 | 0 |
| Gross Profit | 0 | 0 | (1.3M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.16M | 42.24M | 63.94M | 73.3M | 90.3M |
| Selling, General & Admin | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M |
| Operating Expenses | 35.25M | 60.3M | 83.7M | 96.12M | 112.79M |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| EBITDA | (34.41M) | (57.59M) | (74.98M) | (85.58M) | (104.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.25M) | (60.3M) | (84.99M) | (96.12M) | (112.79M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 1.86M | 8.59M | 9.43M | 6.63M |
| Interest Expense | 13K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 1.53M | 8.72M | 9.31M | 6.71M |
| Income Before Tax | (35.25M) | (58.76M) | (76.27M) | (86.81M) | (106.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 137K | 112K | 108K |
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| EPS (Diluted) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| Weighted Avg Shares | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
| Weighted Avg Shares (Diluted) | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.